Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-06-02T03:24:10.363Z Has data issue: false hasContentIssue false

Chapter 26 - Lessons learned: symptomatic trials in early Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges

Published online by Cambridge University Press:  05 March 2016

By
Ramon Lugo-Sanchez  and
Néstor Gálvez-Jiménez
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 280 - 286
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dalaker, TO, Larsen, JP, Bergsland, N, et al. Brain atrophy and white matter hyperintesisites in early Parkisnon's disease. Mov Disord 2009; 24: 2233–41.CrossRefGoogle Scholar
Jakobson, S, Linder, J, Forsgren, L, et al. Pre- and postsynaptic dopamine SPECT in early phase of idiopathic parkinsonism: a population-based study. Eur J Nucl Med Mol Imaging 2010; 37: 2154–64.Google Scholar
Laere, KV, Clerinx, K, D'Hondt, E, de Groot, T, Vandenberghe, W. Combine striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010; 51: 588–95.CrossRefGoogle ScholarPubMed
Evatt, ML, DeLong, MR, Kumari, M, et al. High prevalence of hypovitaminosis D status in patient with early Parkinson disease. Arch Neurol 2011; 68: 314–19.CrossRefGoogle ScholarPubMed
Shiraishi, M, Kobayashi, T, Watanabe, H, Kamo, , Hasegawa, Y. Serum somatostatin in early stage Parkinson's disease. Acta Neurol Scand 2010; 121: 225–9.Google Scholar
Charles, PD, Dolhun, RM, Gill, CE, et al. Deep brain stimulation in early Parkinson's disease: Enrollment experience from a pilot trial. Parkinsonism Relat Disord 2012; 18: 268–73.CrossRefGoogle ScholarPubMed
Gill, CE, Allen, LA, Konrad, PE, et al. Deep brain stimulation of early-stage Parkinson's disease: an illustrative case. Neuromodulation 2011; 14: 515–22.CrossRefGoogle ScholarPubMed
Phillips, L, Litcofsky, KA, Pelster, M, et al. Subthalamic nucleus deep brain stimulation impacts language in early Parkinson's disease. PLoS One 2012; 7: e42829.Google Scholar
Kahn, E, D’Haese, PF, Dawant, B, et al. Deep brain stimulation in early stage Parkinson's disease: operative experience from a prospective randomized clinical trial. J Neurol Neurosurg Psychiatry 2012; 83: 164–70.CrossRefGoogle Scholar
Shill, HA, Obradov, S, Katsnelson, Y, Pizinger, R. A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease. Mov Disord 2011; 26: 1477–80.CrossRefGoogle ScholarPubMed
Hauser, RA, Schapira, AHV, Rasciol, O, et al. Randomized double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010; 25: 2542–9.CrossRefGoogle ScholarPubMed
Schapira, AHV, Barone, P, Hauser, RA, et al. Patient reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advance Parkinson's disease. Eur J Neurol 2013; 20: 50–6.CrossRefGoogle ScholarPubMed
Poewe, W, Rascol, O, Barone, P, et al. Extended-release pramipexole in early Parkinson disease. Neurology 2011; 759–65.CrossRefGoogle ScholarPubMed
Rascol, O, Barone, P, Hauser, RA, et al. Efficacy, safety and tolerability of overnight switching from immediate-to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord 2010; 25: 2326–32.Google Scholar
Parkinson Study Group CALM Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson's disease. Arch Neurol 2009; 66: 563–70.CrossRefGoogle Scholar
Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose parmipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord 2011; 26: 37–44.CrossRefGoogle Scholar
Hauser, RA, Reichmann, H, Lew, M, et al. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. International J Neurosci 2011; 121: 246–53.CrossRefGoogle ScholarPubMed
Watts, RL, Lyons, KE, Pahwa, R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010; 25: 858–66.CrossRefGoogle ScholarPubMed
Bronzova, J, Sampiao, C, Hauser, RA, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010; 25: 738–46.CrossRefGoogle ScholarPubMed
Sampiao, C, Bronzova, J, Hauser, RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large randomized double-blind trials. Mov Disord 2011; 26: 1464–76.CrossRefGoogle Scholar
Shapira, AHV, Stocchi, F, Borgohain, R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol 2013; 20: 271–80.CrossRefGoogle Scholar
Stocchi, F, Borgohain, R, Onofrj, M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27: 106–12.CrossRefGoogle ScholarPubMed
Simuni, T, Borushko, E, Avram, MJ, et al. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord 2010; 25: 2863–6.Google Scholar
Viallet, F, Pitel, S, Lancrenon, S, Blin, O. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Curr Med Res Opin 2013; 29: 23–31.CrossRefGoogle ScholarPubMed
Olanow, W, Hauser, RA, Jankovick, J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design and baseline characteristics. Mov Disord 2008; 23: 2194–201.Google Scholar
Olanow, W, Rascol, O, Hauser, RA, et al. A double blind, delayed-start trial of rasagaline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.CrossRefGoogle Scholar
Hauser, RA, Lew, MF, Hurtig, HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24: 564–73.CrossRefGoogle ScholarPubMed
Schenkman, M, Hall, D, Barón, AE, et al. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther 2012; 92: 1395–410.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×